Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

800

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

Diabetes MellitusType 2 DM

Interventions

COMBINATION_PRODUCT

Empagliflozin+Linagliptin+Metformin

Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients

All Listed Sponsors

lead

Nabiqasim Industries (Pvt) Ltd

INDUSTRY